Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. CS (NQ: MRUS )

44.04 +0.64 (+1.47%)
Streaming Delayed Price Updated: 12:21 PM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 208,104
Open 43.65
Bid (Size) 44.01 (1)
Ask (Size) 44.06 (1)
Prev. Close 43.40
Today's Range 43.33 - 44.45
52wk Range 19.80 - 52.03
Shares Outstanding 46,530,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
From Merus N.V.
Via GlobeNewswire
MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024
MRUS stock results show that Merus beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+53.88%
+53.88%
1 Month
+8.88%
+8.88%
3 Month
-2.13%
-2.13%
6 Month
+86.29%
+86.29%
1 Year
+65.13%
+65.13%

More News

Read More
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Expert Ratings for Merus
Via Benzinga
The Latest Analyst Ratings for Merus
Via Benzinga
10 Analysts Have This to Say About Merus
Via Benzinga
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
From Merus N.V.
Via GlobeNewswire
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
From Gilead Sciences, Inc.
Via Business Wire
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
From Merus N.V.
Via GlobeNewswire
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
From Merus N.V.
Via GlobeNewswire
Merus Announces Business Update Conference Call
From Merus N.V.
Via GlobeNewswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
Via FinancialNewsMedia
Exposures Product Safety
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
From Merus N.V.
Via GlobeNewswire
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
Via FinancialNewsMedia
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.